Literature DB >> 11994139

Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund's adjuvant.

A Shibaki1, S I Katz.   

Abstract

CD4+ T cells differentiate into at least two distinct subsets, Th1 and Th2, that are characterized by their cytokine-producing profiles. In this study, we attempted to delineate whether and how CD4+ T-cell responses could be skewed in one direction or another. BALB/c mice were immunized with chicken ovalbumin (OVA) emulsified with either incomplete or complete Freund's adjuvant (IFA or CFA). When lymph node cells were assessed on day 7, antigen specific proliferation was similarly observed both in the mice immunized with IFA and CFA. In contrast, on day 28 there was a less significant response in the mice primed with IFA than in those primed with CFA. ELISA analyses revealed more Th1 predominant cytokine production by T cells immunized with OVA+CFA rather than in IFA, which resulted in balanced IFN-gamma and IL-4 production. Flow cytometric analyses of intracellular cytokines confirmed that T cells from mice primed with CFA produced Th1 cytokines more predominantly. When lymph node dendritic cells (DC) were compared for their co-stimulatory molecule expression, priming with CFA and IFA similarly upregulated CD80 and CD86 expression by lymph node DC, and no significant differences were observed in CD40, 54, 80 and 86 expression between the DC harvested from IFA and CFA immunized mice. In addition, both priming with IFA and CFA similarly induced IL-12 production by DC. Thus, although the reason(s) for the preferential induction of a Th1/Th2 response remains unknown, these results indicate that a relatively Th1/Th2 skewed response is differentially induced by different types of adjuvants, and induction of a Th1 skewed response may be responsible for long lasting cellular immunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994139     DOI: 10.1034/j.1600-0625.2002.110204.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  26 in total

1.  Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens.

Authors:  Christopher G Earnhart; Richard T Marconi
Journal:  Vaccine       Date:  2007-01-17       Impact factor: 3.641

2.  Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Authors:  Shih-Wen Lin; Scott E Hensley; Nia Tatsis; Marcio O Lasaro; Hildegund C J Ertl
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 3.  Old and new adjuvants.

Authors:  Amy S McKee; Philippa Marrack
Journal:  Curr Opin Immunol       Date:  2017-07-19       Impact factor: 7.486

4.  A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.

Authors:  Olga Pleguezuelos; Stuart Robinson; Ana Fernández; Gregory A Stoloff; Alex Mann; Anthony Gilbert; Ganesh Balaratnam; Tom Wilkinson; Rob Lambkin-Williams; John Oxford; Wilson Caparrós-Wanderley
Journal:  Clin Vaccine Immunol       Date:  2015-05-20

5.  Recombinant Lactococcus Lactis Displaying Omp31 Antigen of Brucella melitensis Can Induce an Immunogenic Response in BALB/c Mice.

Authors:  Hoda Shirdast; Fatemeh Ebrahimzadeh; Amir Hossein Taromchi; Yousef Mortazavi; Abdolreza Esmaeilzadeh; Mohammad Hadi Sekhavati; Keivan Nedaei; Esmat Mirabzadeh
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

6.  Pulmonary endotoxin tolerance protects against cockroach allergen-induced asthma-like inflammation in a mouse model.

Authors:  Sudha Natarajan; Jiyoun Kim; Jacqueline Bouchard; William Cruikshank; Daniel G Remick
Journal:  Int Arch Allergy Immunol       Date:  2012-01-24       Impact factor: 2.749

7.  Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.

Authors:  Michael A Collier; Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Monica M Johnson; Andrew N Macintyre; Gregory D Sempowski; Eric M Bachelder; Jenny P-Y Ting; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2018-10-15       Impact factor: 4.939

Review 8.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

Review 9.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

10.  Normal development and activation but altered cytokine production of Fyn-deficient CD4+ T cells.

Authors:  Alusha A Mamchak; Brandon M Sullivan; Baidong Hou; Linda M Lee; Julia K Gilden; Matthew F Krummel; Richard M Locksley; Anthony L DeFranco
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.